Loading clinical trials...

COMPLETEDPHASE1

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

A Phase 1, Open-Label, Single-Sequence Study to Assess the Effect of Multiple Doses of Omeprazole on the Single-Dose Pharmacokinetics of Bemnifosbuvir/Ruzasvir Fixed-Dose Combination in Healthy Adult Participants

NCT07007806•Atea Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

Drug-drug interaction study between Omeprazole and Bemnifosbuvir/Ruzasvir (BEM/RZR)

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug.
•Minimum body weight of 50 kg and body mass index (BMI) of 18.5-30 kg/m2.
•Willing to comply with the study requirements and to provide written informed consent.

Exclusion Criteria

•Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2.
•Abuse of alcohol or drugs.
•Use of other investigational drugs within 28 days of dosing.
•Concomitant use of prescription medications, or systemic over-the-counter medications.
•Other clinically significant medical conditions or laboratory abnormalities.

Locations (1)

Atea Study Site

Cypress, California, United States

Key Dates

Start Date

May 9, 2025

Primary Completion Date

June 28, 2025

Completion Date

June 28, 2025

Last Updated

August 29, 2025

Enrollment

ACTUAL participants

Conditions

Healthy Volunteer Study

Interventions

Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting

DRUG

Treatment B-Omeprazole 20 mg dose administered fasting

DRUG

Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting

DRUG

Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole

DRUG

Treatment E-Omeprazole 40 mg administered fasting

DRUG

Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole

DRUG

Muscle Vibration as a Countermeasure Against Hypoactivity-induced

NCT07021079

Vibration TherapyHealthy Volunteer Study+1 more

View study

COMPLETEDPHASE1

A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects

NCT06636500

Healthy Volunteer StudyPain Management

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

Inclusion Criteria

Exclusion Criteria

Muscle Vibration as a Countermeasure Against Hypoactivity-induced

A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

Ibuprofen Suspension Bioequivalence Study

A Study Comparing Three Formulations of Ibuprofen in Healthy Subjects